November 27, 2007 - ...In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's , but may also reverse plaque-related brain injuries associated with the disease. The rats tested with the company's proprietary Alzheimer's rat model took on features similar to the crippling signs of dementia seen in human patients suffering from Alzheimer's; by treating the rats with Caprospinol, the rat's brain cells regained complete memory... Samaritan's Press Release -Saturday, December 15, 2007
Samaritan, Favorable Caprospinol Data At Alzheimer's Drug Development Summit
November 27, 2007 - ...In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's , but may also reverse plaque-related brain injuries associated with the disease. The rats tested with the company's proprietary Alzheimer's rat model took on features similar to the crippling signs of dementia seen in human patients suffering from Alzheimer's; by treating the rats with Caprospinol, the rat's brain cells regained complete memory... Samaritan's Press Release -
